Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of DU-176b in patients with non-valvular atrial fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy

Next Previous
X
Search
Trial Profile

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of DU-176b in patients with non-valvular atrial fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ELDERCARE-AF
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 13 Nov 2023 Results of Sub-Analysis assessing efficacy and safety of low-dose edoxaban according to body weight in very elderly patients with atrial fibrillation presented at the American Heart Association Scientific Sessions 2023
    • 11 May 2022 Results of a subanalysis assessed the prognostic outcomes of very elderly non-valvular atrial fibrillation (NVAF) patients ineligible for standard anticoagulation treatment would vary according to B-type natriuretic peptide stratification published in the American Heart Journal
    • 15 Nov 2021 Results of subanalysis assessing effects of edoxaban in extremely elderly patients (aged > 90 Years) presented at the American Heart Association Scientific Sessions 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top